Keros Therapeutics (NASDAQ:KROS) Shares Down 5.7% After Analyst Downgrade

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) traded down 5.7% during mid-day trading on Tuesday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics traded as low as $18.12 and last traded at $18.32. 350,670 shares were traded during mid-day trading, a decline of 24% from the average session volume of 463,453 shares. The stock had previously closed at $19.42.

A number of other equities research analysts have also weighed in on KROS. Bank of America lowered their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Wedbush reiterated an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Scotiabank decreased their target price on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research note on Friday, December 13th. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Keros Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $81.33.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. KBC Group NV raised its holdings in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. raised its holdings in Keros Therapeutics by 36.7% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock worth $223,000 after buying an additional 1,033 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of Keros Therapeutics by 16.3% in the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after buying an additional 1,130 shares in the last quarter. Finally, Algert Global LLC grew its holdings in shares of Keros Therapeutics by 10.6% during the second quarter. Algert Global LLC now owns 15,700 shares of the company’s stock valued at $717,000 after buying an additional 1,505 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

The company has a market cap of $729.13 million, a P/E ratio of -3.45 and a beta of 1.20. The company’s 50-day moving average is $57.46 and its two-hundred day moving average is $52.30.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million during the quarter. During the same period in the prior year, the company earned ($1.33) EPS. Keros Therapeutics’s revenue was up 4750.0% on a year-over-year basis. Equities research analysts anticipate that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.